The FDA will decide whether or not to approve GA Depot 40 mg for the treatment of relapsing forms of multiple sclerosis on March 8, 2024.Viatris Inc. (VTRS) secured an exclusive license to commercialize the GA Depot injection product for relapsing forms of multiple sclerosis under an agreement with Mapi Pharma. GA Depot 40 mg, which is designed to be administered as an intramuscular injection once every four weeks, is a long-acting injection version of the approved Glatiramer Acetate, commercially available as Copaxone. Copaxone and its generics are administered subcutaneously either daily or thrice weekly.GA Depot 40 mg, if approved, offers patients an effective treatment option featuring a more convenient dosing schedule, potentially enhancing compliance and adherence.VTRS closed Tuesday's (Feb.27, 2024) trading at $13.23, down 1.49%.